Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance

Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance

Triplet combinations containing a proteasome inhibitor are a standard of care in newly diagnosed multiple myeloma (NDMM). We examined the long-term efficacy and safety of the all-oral combination of weekly ixazomib plus lenalidomide-dexamethasone (IRd), followed by single-agent ixazomib maintenance...

Full description

Saved in:
Bibliographic Details
Main Authors: Shaji Kumar, Jesús G. Berdeja, Rubén Niesvizky, Sagar Lonial, Jacob P. Laubach, Mehdi Hamadani, A. Keith Stewart, Parameswaran Hari, Vivek Roy, Robert Vescio, Jonathan L. Kaufman, Deborah Berg, Eileen Liao, S. Vincent Rajkumar, Paul G. Richardson
Format: Artigo
Language:English
Published: 2019
Online Access:https://doi.org/10.1038/s41375-019-0384-1
https://www.nature.com/articles/s41375-019-0384-1.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41375-019-0384-1
https://www.nature.com/articles/s41375-019-0384-1.pdf

Similar Items